Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Bioxcel Therapeutics Inc (BTAI)

Bioxcel Therapeutics Inc (BTAI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,418
  • Shares Outstanding, K 6,056
  • Annual Sales, $ 2,270 K
  • Annual Income, $ -59,600 K
  • EBIT $ -53 M
  • EBITDA $ -53 M
  • 60-Month Beta 0.08
  • Price/Sales 3.66
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 68.49%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 841.79% on 11/19/24
  • IV Low 0.00% on 05/21/25
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 11
  • Put/Call OI Ratio 0.18
  • Today's Open Interest 4,164
  • Open Int (30-Day) 4,350

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -2.24
  • Number of Estimates 1
  • High Estimate -2.24
  • Low Estimate -2.24
  • Prior Year -3.36
  • Growth Rate Est. (year over year) +33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3000 +6.92%
on 05/23/25
2.0900 -33.49%
on 04/29/25
-0.3000 (-17.75%)
since 04/23/25
3-Month
1.2900 +7.75%
on 04/07/25
6.8300 -79.65%
on 03/03/25
-0.7400 (-34.74%)
since 02/21/25
52-Week
1.2900 +7.75%
on 04/07/25
30.8800 -95.50%
on 05/31/24
-28.2100 (-95.30%)
since 05/23/24

Most Recent Stories

More News
This Natural Killer Treatment Could Help Transform How Cancer is Treated

GT Biopharma (NASDAQ: GTBP) just initiated the dosing in Cohort 2 of its Phase 1 dose escalation trial evaluating GTB-3650 for the treatment of relapsed or refractory (r/r) CD33 expressing hematologic...

PYXS : 1.2300 (+2.50%)
IOVA : 1.7800 (+1.71%)
BTAI : 1.3900 (+1.46%)
GTBP : 2.89 (+8.24%)
FATE : 1.1600 (-3.33%)
BioXcel Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

BTAI : 1.3900 (+1.46%)
WHO and WEF Are Pushing AI in Global Healthcare -- What It Means for the Market

/CNW/ -- Equity Insider News Commentary – The potential for artificial intelligence (AI) in healthcare is still unfolding, both for patients and providers. A...

AVAI : 0.6222 (-9.73%)
AMST : 2.92 (-4.26%)
BTAI : 1.3900 (+1.46%)
TVGN : 1.3100 (+6.50%)
PLTR : 123.31 (+0.83%)
BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024

BTAI : 1.3900 (+1.46%)
BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

BTAI : 1.3900 (+1.46%)
BioXcel Therapeutics Announces 33% Enrollment in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

BTAI : 1.3900 (+1.46%)
BioXcel Therapeutics Announces Closing of $14 Million Registered Direct Offering

BTAI : 1.3900 (+1.46%)
Unbelievable Stock Gains! Why these 7 Micro, Small, and Mid-Cap Stocks Skyrocketed This Week!

Source: Shutterstock The U.S. stock market has taken a significant hit, marking one of the biggest declines in recent times. All major indices are down, largely due to economic uncertainties, including...

PRCH : 10.13 (+2.74%)
BTAI : 1.3900 (+1.46%)
MPW : 4.58 (+0.44%)
TRNR : 0.7901 (-11.22%)
OMI : 6.45 (-6.25%)
HURN : 148.96 (-1.15%)
ORGO : 2.90 (-2.36%)
ZI : 10.31 (+10.27%)
BioXcel Therapeutics Announces $14 Million Registered Direct Offering

BTAI : 1.3900 (+1.46%)
BioXcel Therapeutics Announces FDA Closed its Inspection of Site for Phase 3 TRANQUILITY II Trial for Acute Treatment of Agitation Associated with Alzheimer’s Dementia

BTAI : 1.3900 (+1.46%)

Business Summary

BioXcel Therapeutics Inc. is a clinical stage biopharmaceutical company. It focuses on drug development which utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company's product portfolio include BXCL501, a sublingual thin film...

See More

Key Turning Points

3rd Resistance Point 1.5600
2nd Resistance Point 1.4900
1st Resistance Point 1.4400
Last Price 1.3900
1st Support Level 1.3200
2nd Support Level 1.2500
3rd Support Level 1.2000

See More

52-Week High 30.8800
Fibonacci 61.8% 19.5766
Fibonacci 50% 16.0850
Fibonacci 38.2% 12.5934
Last Price 1.3900
52-Week Low 1.2900

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar